Ultrasound-aided drug delivery undergoes US trial:
This article was originally published in Clinica
Executive Summary
Ekos has begun an FDA-approved Phase I clinical trial in the US to assess its ultrasound-enhanced drug delivery technology in the treatment of newly-formed clots in leg arteries. Preclinical studies have shown that simultaneously administering ultrasound and a clot-dissolving drug directly into the blocked area could dissolve a clot faster and more completely than using the drug alone. This is because ultrasound energy can help move the drug into hard-to-reach areas of the clot, said the Bothell, Washington-based company.